Kavita Nanda, MD, MHS

Director, Medical Research

Areas of expertise

  • Hormonal contraception and HIV
  • Family planning and HIV integration
  • Clinical trials design and implementation

Projects & Resources

  • Envision FP develops, introduces and expands understanding of contraceptive technologies to enhance method choice and reduce unmet need.

  • The goal of the Contraceptive Technology Innovation (CTI) Initiative is to develop new and strategically important contraceptives, through a strong focus on global partnerships, that ensures wide access to quality, affordable and acceptable products for those most in need.

Published Research

  • Research gaps identified during the 2014 update of the WHO medical eligibility criteria for contraceptive use and selected practice recommendations for contraceptive use
    Dragoman MV, Jatlaoui T, Nanda K, Curtis KM, Gaffield ME
    Contraception 2016 Sep; 94(3): 195-201. [Journal Impact Factor: 2.788]

    This review identifies knowledge gaps and research to strengthen the 2014 updated guidelines of the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use and the WHO Selected Practice Recommendations for Contraceptive Use. The authors present three global topics in detail: intrauterine device initiation among women at high risk for sexually transmitted infections; bidirectional drug–drug interactions with use of hormonal contraception and antiretroviral therapy; and initiation of progestogen-containing contraception following use of ulipristal acetate emergency contraception.

  • Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial
    Nanda K, Callahan R, Taylor D, Wang M, Agot K, Jenkins D, Van Damme L, Dorflinger L, FEM-PrEP study group
    Contraception 2016 Jul; 94 (1): 40-7. [Journal Impact Factor: 2.788]

    This study presents some of the few available data on contraceptive hormone (medroxyprogesterone acetate) levels among women using depot medroxyprogesterone acetate (DMPA) in Africa. The authors found lower than expected levels among DMPA users with documented injections. This finding highlights the need for more data confirming effectiveness of different DMPA products in different populations, including post-marketing surveillance and pharmacokinetic data and chemical/physical tests for product quality assurance.

  • Pre-exposure prophylaxis for HIV infection among African women
    Van Damme L. Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malaheleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D on behalf of the FEM-PrEP study group
    New England Journal of Medicine. 2012; 367 (5): 411-22

    Pre-exposure prophylaxis with antiretroviral drugs has been effective in the prevention of HIV infection in some trials but not in others. This randomized, double-blind, placebo-controlled trial assigned 2,120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. The study was stopped early, on April 18, 2011, because of lack of efficacy. Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low.

Explore More Related to Kavita Nanda, MD, MHS